Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

V. Beral; R. Doll; C. Hermon; R. Peto; G. Reeves; L.J. Schouten; P.A. van den Brandt; Paul N. Appleby

doi:10.1016/S0140-6736(08)60167-1

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

V. Beral, R. Doll, C. Hermon, R. Peto, G. Reeves, L.J. Schouten, P.A. van den Brandt, Paul N. Appleby^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1969 Downloads (Pure)

Abstract

Background oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects.

Original language	English
Pages (from-to)	303-314
Journal	Lancet
Volume	371
Issue number	9609
DOIs	https://doi.org/10.1016/S0140-6736(08)60167-1
Publication status	Published - 1 Jan 2008

Access to Document

10.1016/S0140-6736(08)60167-1

Full TextFinal published version, 292 KB

Cite this

@article{44267649a4c1406ea3284cfdb6d80b24,

title = "Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls",

abstract = "Background oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects.",

author = "V. Beral and R. Doll and C. Hermon and R. Peto and G. Reeves and L.J. Schouten and {van den Brandt}, P.A. and Appleby, {Paul N.}",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/S0140-6736(08)60167-1",

language = "English",

volume = "371",

pages = "303--314",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Science",

number = "9609",

}

TY - JOUR

T1 - Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

AU - Beral, V.

AU - Doll, R.

AU - Hermon, C.

AU - Peto, R.

AU - Reeves, G.

AU - Schouten, L.J.

AU - van den Brandt, P.A.

AU - Appleby, Paul N.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects.

AB - Background oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects.

U2 - 10.1016/S0140-6736(08)60167-1

DO - 10.1016/S0140-6736(08)60167-1

M3 - Article

SN - 0140-6736

VL - 371

SP - 303

EP - 314

JO - Lancet

JF - Lancet

IS - 9609

ER -